Fidelity Investments
INDV icon

Fidelity Investments’s Indivior Pharmaceuticals INDV Stock Holding History

Fidelity Investments’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.5M Sell
402,415
-125,299
-24% -$4.55M ﹤0.01% 1938
2026
Q1 		$16.1M Buy
527,714
+31,074
+6% +$1.03M ﹤0.01% 1861
2025
Q4 		$17.8M Buy
496,640
+427,187
+615% +$13M ﹤0.01% 1817
2025
Q3 		$1.67M Buy
69,453
+69,143
+22,304% +$1.45M ﹤0.01% 2607
2025
Q2 		$4.61K Buy
+310
New +$3.61K ﹤0.01% 4726
2025
Q1 		– Sell
-205
Closed -$2.55K – 5511
2024
Q4 		$2.55K Sell
205
-355
-63% -$3.65K ﹤0.01% 4781
2024
Q3 		$5.5K Sell
560
-6,538,174
-100% -$76.6M ﹤0.01% 4602
2024
Q2 		$102M Buy
6,538,734
+311,919
+5% +$5.63M 0.01% 1029
2024
Q1 		$133M Buy
6,226,815
+1,122,031
+22% +$21.1M 0.01% 950
2023
Q4 		$77.1M Sell
5,104,784
-393,303
-7% -$6.98M 0.01% 1117
2023
Q3 		$119M Buy
5,498,087
+1,915,980
+53% +$43.7M 0.01% 897
2023
Q2 		$82.9M Buy
+3,582,107
New +$82.1M 0.01% 1075

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fidelity Investments's INDV Position: Q2 2026 in Review

Fidelity Investments reduced its Indivior Pharmaceuticals (INDV) stake by 24% in Q2 2026, selling an estimated $4.55M and leaving 402,415 shares worth $16.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1938.

Fidelity Investments first reported a position in INDV in Q2 2023 and has held it in 12 quarters since. The position peaked at $133M in Q1 2024. 339 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Fidelity Investments held 402,415 shares of Indivior Pharmaceuticals worth $16.5M as of Q2 2026.
  • Fidelity Investments sold 125,299 Indivior Pharmaceuticals shares in Q2 2026, an estimated $4.55M.
  • Indivior Pharmaceuticals made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #1938 holding.
  • Fidelity Investments first reported a position in Indivior Pharmaceuticals in Q2 2023 and has held it in 12 quarters since.
  • Fidelity Investments's Indivior Pharmaceuticals position peaked at $133M in Q1 2024.
  • 339 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.